Irlanda - inglés - HPRA (Health Products Regulatory Authority)

abbvie limited - levobupivacaine hydrochloride - solution for injection/infusion - 5.0 milligram(s)/millilitre - amides; levobupivacaine

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

abbvie limited - levobupivacaine hydrochloride - solution for injection/infusion - 7.5 milligram(s)/millilitre - amides; levobupivacaine

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

abbvie limited - glecaprevir 100mg;  ; pibrentasvir 40mg;   - film coated tablet - active: glecaprevir 100mg   pibrentasvir 40mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium hypromellose iron oxide red lactose monohydrate macrogol 3350 propylene glycol monocaprylate sodium stearyl fumarate titanium dioxide tocofersolan - maviret is indicated for the treatment of adults and adolescents 12 years and older with chronic hepatitis c virus (hcv)

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

abbvie limited - levobupivacaine hydrochloride - solution for infusion - 0.625 milligram(s)/millilitre - amides; levobupivacaine

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

abbvie limited - dexamethasone 700ug - intraocular implant - 700 mcg - active: dexamethasone 700ug excipient: polyglactin (poly (d, l-lactide-co-glycolide), 50:50 plga acid) polyglactin - ozurdex® is indicated for the treatment of macular oedema due to retinal vein occlusion (rvo).

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

abbvie limited - bimatoprost 0.3 mg/ml;  ; timolol maleate 6.8 mg/ml equivalent to 5 mg/ml timolol;   - eye drops, solution - active: bimatoprost 0.3 mg/ml   timolol maleate 6.8 mg/ml equivalent to 5 mg/ml timolol   excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid purified water sodium chloride sodium hydroxide

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

abbvie limited - bimatoprost 0.3 mg/ml;   - eye drops, solution - 0.3 mg/ml - active: bimatoprost 0.3 mg/ml   excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid purified water sodium chloride sodium hydroxide - monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

abbvie limited - bimatoprost 0.3 mg/ml;   - eye drops, solution - 0.3 mg/ml - active: bimatoprost 0.3 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid purified water sodium chloride sodium hydroxide - indicated as monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

abbvie limited - paricalcitol - solution for injection - 5 microgram(s)/millilitre - other anti-parathyroid agents; paricalcitol

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

abbvie limited - paricalcitol - solution for injection - 5 microgram(s)/millilitre - other anti-parathyroid agents; paricalcitol